615 related articles for article (PubMed ID: 32406915)
41. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
[TBL] [Abstract][Full Text] [Related]
42. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.
Abbara A; Clarke S; Islam R; Prague JK; Comninos AN; Narayanaswamy S; Papadopoulou D; Roberts R; Izzi-Engbeaya C; Ratnasabapathy R; Nesbitt A; Vimalesvaran S; Salim R; Lavery SA; Bloom SR; Huson L; Trew GH; Dhillo WS
Hum Reprod; 2017 Sep; 32(9):1915-1924. PubMed ID: 28854728
[TBL] [Abstract][Full Text] [Related]
43. Serum progesterone is lower in ovarian stimulation with highly purified HMG compared to recombinant FSH owing to a different regulation of follicular steroidogenesis: a randomized controlled trial.
Bosch E; Alamá P; Romero JL; Marí M; Labarta E; Pellicer A
Hum Reprod; 2024 Feb; 39(2):393-402. PubMed ID: 38037188
[TBL] [Abstract][Full Text] [Related]
44. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization.
Orvieto R; Zohav E; Scharf S; Rabinson J; Meltcer S; Anteby EY; Homburg R
Gynecol Endocrinol; 2007 Feb; 23(2):72-5. PubMed ID: 17454155
[TBL] [Abstract][Full Text] [Related]
45. Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response.
Volodarsky-Perel A; Cohen Y; Arab S; Son WY; Suarthana E; Dahan MH; Tulandi T; Buckett W
Hum Reprod; 2019 Mar; 34(3):530-538. PubMed ID: 30689898
[TBL] [Abstract][Full Text] [Related]
46. The number of oocytes retrieved during IVF: a balance between efficacy and safety.
Magnusson Å; Källen K; Thurin-Kjellberg A; Bergh C
Hum Reprod; 2018 Jan; 33(1):58-64. PubMed ID: 29136154
[TBL] [Abstract][Full Text] [Related]
47. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
[TBL] [Abstract][Full Text] [Related]
49. The optimum number of oocytes in IVF treatment: an analysis of 2455 cycles in China.
Ji J; Liu Y; Tong XH; Luo L; Ma J; Chen Z
Hum Reprod; 2013 Oct; 28(10):2728-34. PubMed ID: 23887075
[TBL] [Abstract][Full Text] [Related]
50. Higher probability of live-birth in high, but not normal, responders after first frozen-embryo transfer in a freeze-only cycle strategy compared to fresh-embryo transfer: a meta-analysis.
Bosdou JK; Venetis CA; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
Hum Reprod; 2019 Mar; 34(3):491-505. PubMed ID: 30689865
[TBL] [Abstract][Full Text] [Related]
51. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
52. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
[TBL] [Abstract][Full Text] [Related]
53. Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective study.
Lin YH; Huang MZ; Hwang JL; Chen HJ; Hsieh BC; Huang LW; Tzeng CR; Seow KM
J Assist Reprod Genet; 2013 Jun; 30(6):753-9. PubMed ID: 23606010
[TBL] [Abstract][Full Text] [Related]
54. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
[TBL] [Abstract][Full Text] [Related]
55. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
56. Is oocyte maturity influenced by ovulation trigger type in oocyte donation cycles?
Jones BP; Al-Chami A; Gonzalez X; Arshad F; Green J; Bracewell-Milnes T; Saso S; Smith R; Serhal P; Ben Nagi J
Hum Fertil (Camb); 2021 Dec; 24(5):360-366. PubMed ID: 31571498
[TBL] [Abstract][Full Text] [Related]
57. There is no evidence that the time from egg retrieval to embryo transfer affects live birth rates in a freeze-all strategy.
Lattes K; Checa MA; Vassena R; Brassesco M; Vernaeve V
Hum Reprod; 2017 Feb; 32(2):368-374. PubMed ID: 27986819
[TBL] [Abstract][Full Text] [Related]
58. Association between body mass index and oocyte maturation in patients triggered with GnRH agonist who are at high risk for severe ovarian hyperstimulation syndrome: an observational cohort study.
Lainas GT; Lainas TG; Sfontouris IA; Venetis CA; Bosdou JK; Chatzimeletiou A; Grimbizis GF; Tarlatzis BC; Kolibianakis EM
Reprod Biomed Online; 2020 Jan; 40(1):168-175. PubMed ID: 31839394
[TBL] [Abstract][Full Text] [Related]
59. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
[TBL] [Abstract][Full Text] [Related]
60. Effect of oocyte donor stimulation on recipient outcomes: data from a US national donor oocyte bank.
Hipp HS; Gaskins AJ; Nagy ZP; Capelouto SM; Shapiro DB; Spencer JB
Hum Reprod; 2020 Apr; 35(4):847-858. PubMed ID: 32142582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
